Skip to content

Study · Observational study · n = 287 · 2024

8 results

Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.

Alabduljabbar K, Alsaqaaby M, Neff KJ, Crotty M, le Roux CW

Endocrine21 Sept 2023Cited by 13 (Europe PMC)

PMID37735340 (opens in a new tab)DOI10.1007/s12020-023-03534-0 (opens in a new tab)PepBankPUB-37735340
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In real-world adults with obesity, injectable semaglutide led to a mean body weight loss of 6.6% after 3 months in patients who completed 3 months.

    In plain wordsIn adults with obesity treated in routine care, semaglutide injections led to an average 6.6% body weight loss after 3 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 3 months
    Study

    n = 287

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 3 monthsAs given in this study (human).

    Measurements

    Body weight loss
    6.6%
    3 months

    Source sentences

    Summary
    287 patients (82%) completed 3 months on injectable semaglutide and lost 6.6 ± 3.8% bodyweight.
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.
  2. 02HumanObservational studyEfficacy outcome

    In real-world adults with obesity, injectable semaglutide led to a mean body weight loss of 12% after 6 months in patients who completed 6 months.

    In plain wordsIn adults with obesity treated in routine care, semaglutide injections led to an average 12% body weight loss after 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 6 months
    Study

    n = 224

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 6 monthsAs given in this study (human).

    Measurements

    Body weight loss
    12%
    6 months

    Source sentences

    Summary
    224 patients (64%) completed 6 months on semaglutide and lost 12 ± 6.1% bodyweight.
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.
  3. 03HumanObservational studyEfficacy outcome

    In real-world adults with obesity, 65.5% of patients who completed 3 months of semaglutide lost 5% or more of body weight.

    In plain wordsIn adults with obesity treated in routine care, about two in three patients lost at least 5% of body weight in 3 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss of 5% or more at 3 months
    Study

    n = 287

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 3 monthsAs given in this study (human).

    Measurements

    Proportion with weight loss >=5%
    65.5%
    3 months

    Source sentences

    Summary
    188 (65.5%) of patients who completed 3-month follow-up lost ≥5% weight
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.
  4. 04HumanObservational studyEfficacy outcome

    In real-world adults with obesity, 13.5% of patients who completed 3 months of semaglutide lost 10% or more of body weight.

    In plain wordsIn adults with obesity treated in routine care, 13.5% of patients lost at least 10% of body weight in 3 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss of 10% or more at 3 months
    Study

    n = 287

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 3 monthsAs given in this study (human).

    Measurements

    Proportion with weight loss >=10%
    13.5%
    3 months

    Source sentences

    Summary
    39 (13.5%) patients lost ≥10% weight
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.
  5. 05HumanObservational studyEfficacy outcome

    In real-world adults with obesity, 2.4% of patients who completed 3 months of semaglutide lost 15% or more of body weight.

    In plain wordsIn adults with obesity treated in routine care, 2.4% of patients lost at least 15% of body weight in 3 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss of 15% or more at 3 months
    Study

    n = 287

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 3 monthsAs given in this study (human).

    Measurements

    Proportion with weight loss >=15%
    2.4%
    3 months

    Source sentences

    Summary
    7 (2.4%) patients lost ≥15% weight
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.
  6. 06HumanObservational studyEfficacy outcome

    In real-world adults with obesity, 89.7% of patients who completed 6 months of semaglutide lost 5% or more of body weight.

    In plain wordsIn adults with obesity treated in routine care, 89.7% of patients lost at least 5% of body weight in 6 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss of 5% or more at 6 months
    Study

    n = 224

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 6 monthsAs given in this study (human).

    Measurements

    Proportion with weight loss >=5%
    89.7%
    6 months

    Source sentences

    Summary
    201 (89.7%) lost ≥5% weight, 135 (60.3%) lost ≥10% weight, and 54 (24.1%) lost ≥ 15% body weight.
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.
  7. 07HumanObservational studyEfficacy outcome

    In real-world adults with obesity, 60.3% of patients who completed 6 months of semaglutide lost 10% or more of body weight.

    In plain wordsIn adults with obesity treated in routine care, about 6 in 10 patients lost at least 10% of body weight in 6 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss of 10% or more at 6 months
    Study

    n = 224

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 6 monthsAs given in this study (human).

    Measurements

    Proportion with weight loss >=10%
    60.3%
    6 months

    Source sentences

    Summary
    135 (60.3%) lost ≥10% weight
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.
  8. 08HumanObservational studyEfficacy outcome

    In real-world adults with obesity, 24.1% of patients who completed 6 months of semaglutide lost 15% or more of body weight.

    In plain wordsIn adults with obesity treated in routine care, 24.1% of patients lost at least 15% of body weight in 6 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss of 15% or more at 6 months
    Study

    n = 224

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    titrated up to 1 mg · injectable · 6 monthsAs given in this study (human).

    Measurements

    Proportion with weight loss >=15%
    24.1%
    6 months

    Source sentences

    Summary
    54 (24.1%) lost ≥ 15% body weight.
    1 context sentence
    Summary · context
    This observational study investigated the response to injectable semaglutide in the first 3 months during the dose titration phase up to 1 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.